Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.56 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.48 |
| ▸ | TSPO | P30536 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017168 | 0.90 | NOTUM (0.49) | NOTUMP2RY14TSPOCYP2C9TMEM97 | |
| SCHEMBL2120020 | 0.85 | NOTUM (0.64) | NOTUMP2RY14TSPOCYP2C9TMEM97 | |
| SCHEMBL8607133 | 0.84 | NOTUM (0.62) | NOTUMP2RY14TSPOCYP2C9TMEM97 | |
| SCHEMBL1221908 | 0.83 | S1PR1 (0.41) | NOTUMP2RY14TSPOCYP2C9TMEM97 | |
| SCHEMBL4683255 | 0.76 | NOTUM (0.59) | NOTUMP2RY14TSPOCYP2C9TMEM97 | |
| SCHEMBL20845555 | 0.75 | NOTUM (0.67) | NOTUMP2RY14TSPOCYP2C9TMEM97 | |
| SCHEMBL12017169 | 0.74 | NOTUM (0.41) | NOTUMP2RY14TSPOCYP2C9TMEM97 | |
| SCHEMBL15104516 | 0.73 | NOTUM (0.60) | NOTUMP2RY14TSPOCYP2C9TMEM97 | |
| SCHEMBL103310 | 0.72 | NOTUM (0.70) | NOTUMP2RY14TSPOCYP2C9TMEM97 | |
| SCHEMBL15104544 | 0.72 | NOTUM (0.59) | NOTUMP2RY14TSPOCYP2C9TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220603-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220603-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| EP-2473488-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | Zalicus Pharmaceuticals Ltd. (CA) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011026241-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220603-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | CACNA1B, SCN1A, CACNA1I | NOTUM 2877/4885P2RY14 220/4885TSPO 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.